Staphylococcus aureus is a commonly found bacteria on the skin and in the nares of healthy people (Centers for Disease Control and Prevention, 2006). However, when bacteria cause an infection, it is the primary reason patients present to emergency departments with skin and soft tissue infections (SSTIs). The SSTIs have changed over the past four decades from methicillin-susceptible S. aureus to methicillin-resistant S. aureus (MRSA). Formerly hospital acquired, these community-acquired infections are now referred to as community-acquired MRSA (CA-MRSA). Therefore, healthcare providers now need to be more vigilant in assessing, diagnosing, and treating CA-MRSA. The treatment plan should consist of pharmacotherapy (e.g., combination therapy) and may also include incision and drainage where indicated. Treatment plans must meet the needs of the patients and match the severity of the infection. In addition to the recognition of MRSA in at-risk populations and educating the patient, the education of advanced practice nurses is also an important aspect if the spread of MRSA within the community is to be contained. This article discusses current MRSA assessment, diagnosis, and treatment recommendations. The article concludes with a MRSA case study.
M ETHICILLIN-RESISTANT Staphylococcus aureus (MRSA) infections have shifted to community-acquired infections, now known as communityacquired MRSA (CA-MRSA). CA-MRSA infections presenting as skin and soft tissue infections (SSTIs) are the most frequent bacterial infections seen in emergency departments (EDs) in the United States (Centers for Disease Control and Prevention [CDC] , methicillin and other narrow-spectrum β-lactamase-resistant penicillin antibiotics (Foster, 1996) . Researchers recently noted that an increasing proportion of MRSA isolates are from community-associated isolates when compared with hospital-associated isolates (Salgado, Farr, & Calfee, 2003) . In the United States, the CDC has designated two MRSA clones as USA 300 and USA 400. These clones have been identified as the primary strains responsible for CA-MRSA infections in the United States (McDougal et al., 2003) . The current strains of CA-MRSA are characterized by the Paton-Valentine leukocidin (PLV) gene, which is thought to be a virulence factor for SSTI (Nicole, 2006) .
Although MRSA infections can involve many organ systems, including respiratory, gastrointestinal, musculoskeletal, and soft tissue and skin, incidence of SSTIs is increasing in the community. The prevalence of CA-MRSA infections among patients with sporadic SSTIs revealed that patients with community-acquired SSTI caused by MRSA are increasing. A recent study implicated CA-MRSA as the most common cause of community-acquired SSTIs in California (Moran, Amii, Abrahamian, & Talan, 2005) . CA-MRSA is spreading, and has exceeded 70% of SSTIs in Atlanta and Houston (Hawkes et al., 2007) Other studies have also implied CA-MRSA as one of the more common SSTIs in other regions of the United States and Europe (Frazee et al., 2005; Vandenesch et al., 2003) .
The highest rates of CA-MRSA infections are reported in urban populations and among the poor. Outbreaks have been noted within groups such as Native American communities, prisons, and athletes who share equipment or towels (Fazee et al., 2005) . Anecdotally, many patients with CA-MRSA present to EDs with chief complaints of spider or insect bites, ingrown hairs, and boils. A study of ED patients with SSTI, showed MRSA in 49.6% of subjects (Frazee et al., 2005) . Clinicians should have a high index of suspicion for CA-MRSA when examining patients with SSTIs.
RISK FACTORS
Those at risk for CA-MRSA include children and the elderly, immunocompromised patients, individuals who participate in contact sports, those in crowded or unsanitary living conditions, persons on recent antimicrobial therapy, and those in contact with healthcare workers. Fleming, Brown, and Tice (2006) reported persons with a history of substance abuse and children in day care centers and their childcare providers as those at highest risk for CA-MRSA infection.
Other risk factors include previous CA-MRSA infection or contact with infected individuals. Comorbid factors that may increase risk include tobacco use and diabetes mellitus (Fleming et al., 2006) . However, there have been cases of CA-MRSA infection in patients with no apparent risk factors (Fridkin et al., 2005) .
CARRYING PATTERNS
Three patterns of carriage have been described in the literature, which include those who (1) always carry a strain, (2) intermittently carry the organism with changing strains, and (3) never carry strains (von Eiff, Becker, Machka, Stammer, & Peters, 2001) . The third group, those who never carry strains, is in the minority. Persistent carriage has been discovered to be more common in children than in the adult population (Tolan & Baorto, 2006) .
The common bacterial etiology of community-acquired SSTIs has generally been gram-positive organisms such as S. aureus and Streptococcus pyogenes. As the pathogens associated with these infections have been predictable, most providers have not routinely performed cultures for SSTIs. However, obtaining cultures is now of great importance to monitor the extent of CA-MRSA infection in the community and to guide therapy in areas in which CA-MRSA is already prevalent (Moran et al., 2005) .
120
Advanced Emergency Nursing Journal
COLONIZATION
Staphylococcus aureus is most consistently isolated in the anterior nares, and this is considered colonization. How colonization relates to infection is not completely understood, but is associated with factors of the host and the strain of S. aureus (Graham, Lin, & Larson, 2006) . Frazee et al. (2005) reported a correlation of the strain of bacteria between nasal cultures and wound cultures, although with a lower yield for the former culture. This lower yield in nasal culture was attributed to sampling error. In addition, the lower yield was also attributed to the fact that S. aureus was, at times, colonized in the axilla and in the groin. These researchers further indicated that positive MRSA cultures of the nares and corresponding positive wound cultures demonstrated identical clones, supporting nasal colonization with MRSA as a reservoir for infection (Frazee et al., 2005) .
TREATMENT RECOMMENDATIONS
There are no absolute standards for the treatment of the patient with CA-MRSA infection, although there are many recommendations. Patients with CA-MRSA infection are treated as inpatients or outpatients with a variety of antibiotic medications (Table 1) . Intravenous (IV) antibiotics are administered to patients who have comorbidities, severe SSTIs, or recurrent infections. These individuals are admitted and cared for as inpatients. Some patient requiring IV antibiotic may receive this therapy in the ED (e.g., patients without comorbidities and less-severe infections). These ED patients are then discharged home on oral antibiotics and may return to the ED for follow-up within 8 to 12 hr and/or will be referred to their primary care physician within 24 hr.
Incision and Drainage
In both the inpatient and outpatient settings, incision and drainage (I&D) is considered to be the mainstay of treatment for abscesses. It is a medical and surgical necessity and is not considered an elective procedure. Antibiotics do not penetrate an abscess, and the pus from a lesion must be adequately drained for proper healing (Usatine, Moy, Tobnick, & Siegel, 1998) . I&D must be performed correctly to provide adequate drainage. Inadequate incision is the most common error in performing I&D in patients with SSTI who were treated with antibiotic therapy, and failed did not have a higher incidence of MRSA than those found to have methicillinsusceptible S. aureus. This suggests that inadequate drainage was one cause of treatment failure (Moran et al., 2005) .
Patients diagnosed with communityacquired SSTI were previously treated with I&D with or without antibiotic, usually a cephalosporin. This regimen alone is no longer considered adequate for patients with CA-MRSA infections (Moran et al., 2005) .
Needle Aspiration
Needle aspiration for pus is a diagnostic tool rather than a therapeutic treatment modality. If the lesion is questionable for the abscess versus cellulitis diagnosis, it is reasonable to perform a needle aspiration. If pus or fluid is aspirated, I&D is the definitive treatment. Nicole (2006) recommended that minor SSTIs without suspicion for CA-MRSA could be treated with topical agents such as mupirocin (Bactroban) ointment as one such topical agent. Definitive determination for the presence of CA-MRSA is done by culture. Suspicion for CA-MRSA is increased in communities where it is known to be prevalent and in patients with spontaneous abscess or furunculosis (Frazee et al., 2005) . Frazee et al. (2005) suggested that SSTIs requiring antibiotics be treated with agents that are effective against CA-MRSA. They also recommend the addition of an agent to cover S pyogenes, such as cephalexin. There are multiple oral antibiotic therapy recommendations for MRSA that are listed in Table 1 . Clindamycin, trimethoprim/ sulfamethoxazole, and rifampin have been recommended as agents for the treatment of CA-MRSA, although there has been some reported inducible clindamycin resistance in vitro but not in vivo studies (King et al., 2006) . Doxycycline has been recommended for minor CA-MRSA infections in adults. A study by Frazee et al. (2005) reports 100% susceptibility to trimethoprim/sulfamethoxazole and 85.7% susceptibility to tetracycline. The combination of trimethoprim/sulfamethoxazole and rifampin is found to be more effective in eradicating MRSA colonization (Moran et al., 2005) Chlorhexidine washes and mupirocin ointment are considered reasonable measures in the treatment of patients with recurrent SSTI (Morgan et al., 2005) . Recent research indicates that fluoroquinolones are not recommended as first-line therapy because previous experience has demonstrated the rapid development of resistance (Nicole, 2006) . Cunha (2006) recommends serious or fulminant infections due to CA-MRSA be treated with antibiotics known to be effective against hospital-acquired MRSA (HA-MRSA), as they are also effective against CA-MRSA. Vancomycin is an antibiotic known to be effective against HA-MRSA and CA-MRSA (King et al., 2006) . It is primarily reserved for more severe infections and is usually part of inpatient therapy, although not in all cases. There is some concern that as CA-MRSA is a rapidly evolving bacterium, resistance will develop against the currently used IV and oral antibiotics.
Pharmacologic Therapy
SSTIs suspected of being caused by CA-MRSA should be treated with empiric therapy (Nicole, 2006) . Surveillance for MRSA and S. aureus should be considered to direct empiric therapy (Hawkes et al., 2007) . Area hospital antibiotograms may be useful in determining empiric therapy (Table 2) .
EDUCATION AND PREVENTION
Healthcare providers and staff have an important role in patient education regard-ing transmission, treatment, and containment of infections including CA-MRSA infections. Education is an important component of the treatment plan and is aimed at prevention of the spread of CA-MRSA from an infected or colonized individual to family or community. Primarily, this means emphasizing and encouraging good hygiene, as this limits transmission (Hawkes et al., 2007) .
Adequate hand washing is the primary hygienic measure. Others include keeping wounds covered and to implement respiratory etiquette. Family members who are caregivers should be instructed to wear gloves when handling bodily fluids. These bodily fluids should be specified; in this case, wound drainage or dressings contaminated with wound drainage. Patients and family members should also be instructed to wash their hands after removing their gloves (Blazys, 2001) .
In homes where a family member has CA-MRSA infection, household cleaning products are sufficient for cleaning the environment, laundry, and utensils. Individuals who have open wounds should be advised not to participate in contact sports if the wound cannot be covered. They should not use public whirlpools or spas until the wound has healed, and are advised not to share personal care items such as razors, towels, and soap (Hawkes et al., 2007) .
Finally, a protein-polysaccharide conjugate vaccine has been developed. This vaccine has only been tested in patients on dialysis (Shinefield et al., 2002) . The vaccine has not been tested to date in healthy individuals. In addition, although this vaccine shows promise, it has not been yet been approved by the Food and Drug Administration (CDC, 2006) .
CASE STUDY
The following case study describes a patient with CA-MRSA infection.
History of Present Illness
A 64-year-old obese woman presented to the ED with a complaint of "multiple boils"on her posterior right thigh. She reported that these boils "have been there for approximately 1 week." During that time, she stated that these boils had become progressively more painful. On the date of presentation to the ED, she noticed drainage from the thigh area, which caused her to become concerned enough to seek treatment at the local ED. The patient was not on any medications and she denies any past medical history. She indicated that she was visiting her family in southern California and was due to return home in a few days. She denies any tobacco or alcohol use and denied any history of recreational drug use.
The patient complained of pain in the thigh area with drainage, but did not have any other associated symptoms. She denied fever or chills. Review of systems was otherwise negative. The patient has not had any similar outbreaks and had not had any treatment for this particular illness episode.
Clinical Presentation
The patient weighed 86 kg and her height was 152.4 cm. She presented to the ED with four erythematous, well-circumcised lesions on the posterior aspect of the right thigh (see Figs 1-3) . The lesions were firm with fluctuance and warm, but not hot to touch. The lesions were clustered, and two of the lesions were in proximity causing concern that Figure 1. Carbuncle. there might be tunneling (i.e., subcutaneous wound infection of an artificial passage into the body that has been kept patent).
Diagnostic Studies
The patient had several laboratory studies done including a complete blood count (CBC) ( Table 3 ) and a comprehensive metabolic panel (CMP) ( Table 4 ). The CBC showed an elevated white blood count (WBC). The CMP showed an elevated total protein (TP), which is elevated with chronic inflammation or infection. The glucose and the remainder of CMP were within the reference ranges. The patient also had a wound culture obtained during the I&D process, with the results returned 2 days following the patient's initial presentation (Tables 5 and 6 ). Note. WBC = white blood cells; HGB = hemoglobin; HCT, hematocrit; PLT = platelets; MCV = mean corpuscular volume; RBC = red blood cells; MCH = mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; MVP = mean volume of platelets; NEUTS#; = number of neutrophils; LYMPHS# = number of lymphocytes; MONOS# = number of monocytes; EOS# = number of eosinophils; BASOS# = number of basophils; NEUTS% = percentage of neutrophils; LYMPHS% = percentage of lymphocytes; MONOS% = percentage of monocytes; EOS% = percentage of eosinophils; H = high; and L = low.
Treatment Plan
This patient had multiple lesions that required I&D. There was concern for the possibility of diabetes given the patient's obesity, therefore laboratory studies were obtained. As there were multiple extensive lesions, it was felt that an initial dose of IV antibiotics should be given while the treatment plan was developed. Three of the lesions on the posterior thigh were erythematous, indurated with central fluctuance, with small purulent fluid draining. This was a clear indication for I&D. The Note. NA = sodium; K = potassium; CL = chloride; GLU = glucose; BUN = blood ureanitrogen; CREA = creatinine; TP = total protein; ALB = albumin; T BIL = total bilirubin; CA = calcium; AST = aspartate aminotransferase; ALP = alkaline phosphatase; CO 2 = carbon dioxide; ALT = alanine aminotransferase; and H = high. a Total protein is elevated with chronic inflammation or infection.
procedure was explained to the patient and consent was obtained. The patient was given IV pain medication 4 mg morphine sulfate with 12.5 mg promethazine for nausea prior to the I&D procedure. 
ED Procedure: I&D
The wounds were prepared, draped, and cleansed. A topical anesthetic was applied to the affected areas. The wounds were then anesthetized with 1% lidocaine, with good surface infiltration using a #11 scapel, a 1-cm incision was made over each wound. The wounds were explored. There was no foreign body or deep structure injury. The wounds were irrigated with isotonic sodium chloride solution. All loculated areas (0.9%) were broken up. Moderate amounts of purulent drainage were removed from each of the lesions (Figs 1-3) . None of the lesions tunneled or were communicating. Iodoform gauze 1 / 4 inch was packed into each wound. Dry sterile dressings were applied. The patient tolerated the procedure extremely well and had no adverse reaction to the topical or anesthetic agents that were applied. At the time of discharge, the patient complained of less pain and her wounds were less erythematous. The patient and her family member were given discharge instructions including wound care and follow-up instructions. The patient and family member were also instructed on appropriate hand washing methods, how to care for the wounds, and measures to prevent the spread of infection to other family members.
CASE DISCUSSION
Although the patient had an elevated WBC, she was not septic appearing with abnormal vital signs (i.e., temperature elevation, tachycardia, low blood pressure). Since the patient was afebrile with vital signs within normal limits, it was determined that the patient would be discharged home on oral antibiotics with close follow-up (i.e., within 24 hr). The patient was brought back to the ED on two subsequent visits within 24 hr with significant improvement. The patient's erythema improved, the soft tissue swelling decreased, and there was no further drainage from the wound. The patient was able to return home. She followed up with her primary care provider for further evaluation. This patient had an SSTI, suspected of being caused by CA-MRSA. She had multiple abscesses and was treated as an outpatient. A case could be made for admission for IV antibiotics, given the multiple lesions and the elevated WBC, but the patient's clinical presentation did not indicate sepsis. The patient was afebrile and tolerated fluids well. Although multiple lesions were noted, they were fairly localized. The patient was morbidly obese, but had no other comorbid factors including diabetes.
The appearance and evaluation of the lesions clearly indicated the need for I&D. The patient tolerated the procedure well, and it was felt that each of the lesions was thoroughly drained and washed out. Packing was placed on all sites. Culture with sensitivity was obtained to ensure that antibiotic therapy would be appropriate and to verify the suspicion of CA-MRSA (see Table 6 ).
As these SSTIs were suspected of being caused by CA-MRSA, the patient was placed on antibiotics. Given the extent and number of lesions, the patient was given IV vancomycin. The patient was taking food and 17: fluids and was not septic appearing. The patient was managed on oral antibiotics (i.e., trimethoprim/sulfamethoxazole [Septra or Bactrim DS]). The antibiotogram for this facility showed CA-MRSA, susceptible primarily to tetracycline, clindamycin, and trimethoprim/ sulfamethoxazole. Trimethoprim/ sulfamethoxazole was chosen because the patient was not allergic to this medication, was inexpensive, and it could be prescribed twice a day (i.e., b.i.d.) to facilitate patient medication adherence.
There are a variety of ways that this patient could have been managed. Patient management may also have consisted of inpatient hospitalization with IV antibiotics, combination oral antibiotic therapy, and frequent follow-up visits with close patient monitoring. Although there are multiple different recommendations and guidelines, there is no one definitive standard of care for the treatment of CA-MRSA infection. Healthcare providers should assess risk factors, comorbidity, regional trends, living and social conditions, and patient and community resources when establishing an individualized treatment plan for patients with CA-MRSA infection.
SUMMARY AND CONCLUSION
In summary, CA-MRSA infections range from minor pustules to lesions with systemic involvement. Severe and fatal infections resulting from CA-MRSA, including sepsis and necrotizing fasciitis, have been seen in otherwise healthy patients (Hawkes et al., 2007) . As the epidemiology of the infection changes, the approach and treatment for healthcare providers has also changed. Providers must be vigilant to assessing and diagnosing MRSA. The treatment plan includes I&D where indicated and appropriate pharmacotherapy. In addition to the recognition of MRSA and at-risk populations, education of ED staff, the patient, and the family must also be considered when deciding on the treatment plan to contain the spread of MRSA within the community.
